- Home
- BYON vs CTNM Comparison
BYON vs CTNM Comparison
Compare BYON & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYON
- CTNM
- Stock Information
- Founded
- BYON 1997
- CTNM 2009
- Country
- BYON United States
- CTNM United States
- Employees
- BYON N/A
- CTNM N/A
- Industry
- BYON Catalog/Specialty Distribution
- CTNM
- Sector
- BYON Consumer Discretionary
- CTNM
- Exchange
- BYON Nasdaq
- CTNM Nasdaq
- Market Cap
- BYON 450.6M
- CTNM 453.0M
- IPO Year
- BYON N/A
- CTNM 2024
- Fundamental
- Price
- BYON $5.73
- CTNM $14.18
- Analyst Decision
- BYON Buy
- CTNM Strong Buy
- Analyst Count
- BYON 9
- CTNM 4
- Target Price
- BYON $17.13
- CTNM $29.25
- AVG Volume (30 Days)
- BYON 2.7M
- CTNM 81.0K
- Earning Date
- BYON 10-24-2024
- CTNM 11-06-2024
- Dividend Yield
- BYON N/A
- CTNM N/A
- EPS Growth
- BYON N/A
- CTNM N/A
- EPS
- BYON N/A
- CTNM N/A
- Revenue
- BYON $1,476,271,000.00
- CTNM N/A
- Revenue This Year
- BYON N/A
- CTNM N/A
- Revenue Next Year
- BYON $3.58
- CTNM N/A
- P/E Ratio
- BYON N/A
- CTNM N/A
- Revenue Growth
- BYON N/A
- CTNM N/A
- 52 Week Low
- BYON $5.57
- CTNM $12.33
- 52 Week High
- BYON $37.10
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- BYON 26.96
- CTNM N/A
- Support Level
- BYON $5.57
- CTNM N/A
- Resistance Level
- BYON $6.51
- CTNM N/A
- Average True Range (ATR)
- BYON 0.38
- CTNM 0.00
- MACD
- BYON 0.07
- CTNM 0.00
- Stochastic Oscillator
- BYON 13.72
- CTNM 0.00
About BYON Beyond Inc.
Beyond Inc is an online retailer that provides products and services through websites. The company offers a broad range of products, including furniture, décor, area rugs, bedding and bath, home improvement, outdoor, and kitchen and dining items, BMMG (like books, magazines, CDs), electronics, and other items. The home and garden product line accounts for a material part of its total revenue. The company operates through a direct business that makes sales from the company's own inventory, and a partner business that sells merchandise from manufacturers, distributors, and other suppliers through the company's websites. The company generates the majority of its total revenue from partner business in terms of business format, and from the U.S. in terms of market.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.